Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Climb Bio, Inc. (CLYM) had Stock-Based Compensation of $5.56M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-73.90M |
|
-- |
|
-- |
|
$82.02M |
|
$-82.02M |
|
$8.12M |
|
$-73.90M |
|
$-73.90M |
|
$-73.90M |
|
$-73.90M |
|
$-73.90M |
|
$-73.90M |
|
$-82.02M |
|
$-82.78M |
|
48.16M |
|
48.16M |
|
$-1.53 |
|
$-1.53 |
|
| Balance Sheet Financials | |
$154.87M |
|
-- |
|
$62.31M |
|
$217.19M |
|
$4.93M |
|
-- |
|
$0.38M |
|
$5.31M |
|
$211.88M |
|
$211.88M |
|
$211.88M |
|
67.26M |
|
| Cash Flow Statement Financials | |
$-15.56M |
|
$-121.09M |
|
$130.73M |
|
$93.11M |
|
$87.23M |
|
$-5.88M |
|
|
Stock-Based Compensation |
$5.56M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
31.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.88% |
|
-34.88% |
|
-34.02% |
|
-34.88% |
|
$3.15 |
|
$-0.32 |
|
$-0.32 |
|